Liver X Receptor Beta (LXRβ; NR1H2)

The liver X receptors, LXRA (NR1H3; MIM 602423) and LXRB, form a subfamily of the nuclear receptor superfamily and are key regulators of macrophage function, controlling transcriptional programs involved in lipid homeostasis and inflammation. The inducible LXRA is highly expressed in liver, adrenal gland, intestine, adipose tissue, macrophages, lung, and kidney, whereas LXRB is ubiquitously expressed. Ligand-activated LXRs form obligate heterodimers with retinoid X receptors (RXRs; see MIM 180245) and regulate expression of target genes containing LXR response elements (summary by Korf et al., 2009 [PubMed 19436111]).[supplied by OMIM, Jan 2010]

(From RefSeq)

NRR Pathway



Liver X Receptor Beta Sculpture

(From Structure)



(From Aceview)

There are 69 articles specifically referring to this gene in PubMed. Functionally, the gene has been tested for association to diseases (Cholesterol, HDL/blood*; obesity; Tuberculosis, Pulmonary) and proposed to participate in processes (cellular lipid metabolic process, cholesterol homeostasis, lipid homeostasis, negative regulation of gene-specific transcription from RNA polymerase II promoter, negative regulation of proteolysis and 5 others). Proteins are expected to have molecular functions (metal ion binding, retinoid X receptor binding, sequence-specific DNA binding, steroid hormone receptor activity and 3 others) and to localize in nucleus. Putative protein interactors have been described (FOXO3, ING3, MDFI, MED1, NCOA3, NCOA6, NCOR1, NCOR2, NR0B2, NR1H2 and 10 others). 

(From HuGENavigator)

  • Alzheimer Disease 
  • Diabetes Mellitus, Type 2 
  • Cardiovascular Diseases 
  • Inflammation 
  • Metabolic Syndrome X 
  • Neoplasms 
  • Obesity 
  • Osteoporosis 
  • Pre-Eclampsia 
  • Prediabetic State 
  • Inflammatory Bowel Diseases 
  • Insulin Resistance 
  • Kidney Failure, Chronic 
  • Lymphoma, Non-Hodgkin 
  • Colitis, Ulcerative 
  • Coronary Artery Disease 
  • Coronary Disease 
  • Crohn Disease 
  • Dementia 
  • Diabetes Complications 
  • Edema 
  • Encephalitis 
  • Gallbladder Neoplasms 
  • Atherosclerosis 
  • Calcinosis 

Assay Kits and Services are available from INDIGO Biosciences.

Kits are offered in different assay formats to accommodate researchers’ needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications. Assay systems are all inclusive, providing reporter cells, optimized growth media, media for diluting test compounds, a positive-control agonist, luciferase detection reagent, a white assay plate, a detailed protocol, and a protocol quick guide. All kits are shipped on dry ice.

LXRβ Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

The principle application of this assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the liver x receptor. This kit product is an all-inclusive assay system that includes, in addition to LXRβ Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.


(From Aceview)

The gene contains 21 distinct gt-ag introns. Transcription produces 13 alternatively spliced mRNAs. There are 5 probable alternative promotors, 2 non overlapping alternative last exons and 5 validated alternative polyadenylation sites (see the diagram). The mRNAs appear to differ by truncation of the 5' end, truncation of the 3' end, presence or absence of 5 cassette exons, overlapping exons with different boundaries, splicing versus retention of 8 introns. 75 bp of this gene are antisense to spliced gene NAPSB, raising the possibility of regulated alternate expression. Note that mRNA .lAug10 was found in vivo, although it is a predicted target of nonsense mediated mRNA decay (NMD). Efficacy of translation may be reduced by the presence of a shorter translated product (uORF) initiating at an AUG upstream of the main open reading frame (in variant bAug10, cAug10, dAug10, eAug10, fAug10). 




(From KEGG)

None noted

(From BioGPS)